In this issue of Rheumatic Disease Clinics, guest editor Dr. R. Hal Scofield brings his considerable expertise to the topic of Sj�gren’s Disease. This issue discusses emerging drugs, covering new targeted therapies in Sj�gren's, including recent phase 2 trial results; provides an update on current guidelines, authored by leading figures in the Sj�gren's Foundation Clinical Practice Guidelines committee; provides up-to-date coverage of genetics, reflecting the growing shift towards precision medicine and genetic risk stratification, one of the most rapidly evolving areas in rheumatology; and more.
